We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Perrigo to Report Q3 Earnings: Is a Beat in Store for the Stock?
Read MoreHide Full Article
Key Takeaways
Perrigo will report Q3 2025 earnings on Nov. 5, with estimates at $1.10B in sales and $0.75 EPS.
Higher product pricing likely aided both CSCA and CSCI units, offset by exited businesses.
Perrigo's recent earnings track record shows mixed results, with shares down 19% year to date.
Perrigo Company plc (PRGO - Free Report) is scheduled to report third-quarter 2025 earnings on Nov. 5, before the opening bell. The company’s earnings missed estimates by 3.39% in the last reported quarter.
The Zacks Consensus Estimate for sales and earnings is pegged at $1.10 billion and 75 cents per share, respectively.
Factors Shaping PRGO’s Upcoming Results
Perrigo reports its results under two segments — Consumer Self Care Americas (“CSCA”) and Consumer Self Care International (“CSCI”).
We expect third-quarter sales across both segments to have benefited from higher net price realization for its products through strategic price increases, partially offset by the impact of exited businesses and product lines.
The Zacks Consensus Estimate and our model estimate for CSCA sales are pegged at $664 million and $676 million, respectively. For the CSCI segment, the Zacks Consensus Estimate is pinned at $432 million, while our model estimate for sales is pegged at $429 million.
We expect the company to provide an update on the expected impact of macroeconomic pressures in the upcoming quarters.
PRGO’s Earnings Surprise History
The company’s earnings performance has been mixed over the trailing four quarters. Its earnings beat estimates in two of the last four quarters and missed the mark on the other two occasions, delivering an average surprise of 0.91%.
Year to date, Perrigo’s shares have lost 19% against the industry’s 1% growth.
Image Source: Zacks Investment Research
What Our Model Predicts for PRGO Stock
Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of delivering an earnings beat. This is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Perrigo has an Earnings ESP of -1.33% and a Zacks Rank #4 (Sell) at present.
Here are some drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
ANI Pharmaceuticals (ANIP - Free Report) has an Earnings ESP of +10.55% and a Zacks Rank #2.
ANIP stock has risen 64% so far this year. The company beat earnings estimates in each of the last four reported quarters, delivering an average earnings surprise of 22.66%. ANI Pharmaceuticals is scheduled to report third-quarter results on Nov. 7.
CRISPR Therapeutics (CRSP - Free Report) has an Earnings ESP of +3.53% and carries a Zacks Rank #3 at present.
Shares of CRSP have surged nearly 63% year to date. CRISPR Therapeutics beat on earnings in three of the trailing four quarters and missed in one, delivering an average surprise of 18.41%.
Immunocore (IMCR - Free Report) has an Earnings ESP of +30.39% and carries a Zacks Rank #3 at present.
The stock has increased by over 12% year to date. Immunocore beat on earnings in three of the trailing four quarters and missed in one, delivering an average surprise of 65.14%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Perrigo to Report Q3 Earnings: Is a Beat in Store for the Stock?
Key Takeaways
Perrigo Company plc (PRGO - Free Report) is scheduled to report third-quarter 2025 earnings on Nov. 5, before the opening bell. The company’s earnings missed estimates by 3.39% in the last reported quarter.
The Zacks Consensus Estimate for sales and earnings is pegged at $1.10 billion and 75 cents per share, respectively.
Factors Shaping PRGO’s Upcoming Results
Perrigo reports its results under two segments — Consumer Self Care Americas (“CSCA”) and Consumer Self Care International (“CSCI”).
We expect third-quarter sales across both segments to have benefited from higher net price realization for its products through strategic price increases, partially offset by the impact of exited businesses and product lines.
The Zacks Consensus Estimate and our model estimate for CSCA sales are pegged at $664 million and $676 million, respectively. For the CSCI segment, the Zacks Consensus Estimate is pinned at $432 million, while our model estimate for sales is pegged at $429 million.
We expect the company to provide an update on the expected impact of macroeconomic pressures in the upcoming quarters.
PRGO’s Earnings Surprise History
The company’s earnings performance has been mixed over the trailing four quarters. Its earnings beat estimates in two of the last four quarters and missed the mark on the other two occasions, delivering an average surprise of 0.91%.
Perrigo Company plc Price and EPS Surprise
Perrigo Company plc price-eps-surprise | Perrigo Company plc Quote
Year to date, Perrigo’s shares have lost 19% against the industry’s 1% growth.
Image Source: Zacks Investment Research
What Our Model Predicts for PRGO Stock
Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of delivering an earnings beat. This is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Perrigo has an Earnings ESP of -1.33% and a Zacks Rank #4 (Sell) at present.
You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks With Favorable Combination
Here are some drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
ANI Pharmaceuticals (ANIP - Free Report) has an Earnings ESP of +10.55% and a Zacks Rank #2.
ANIP stock has risen 64% so far this year. The company beat earnings estimates in each of the last four reported quarters, delivering an average earnings surprise of 22.66%. ANI Pharmaceuticals is scheduled to report third-quarter results on Nov. 7.
CRISPR Therapeutics (CRSP - Free Report) has an Earnings ESP of +3.53% and carries a Zacks Rank #3 at present.
Shares of CRSP have surged nearly 63% year to date. CRISPR Therapeutics beat on earnings in three of the trailing four quarters and missed in one, delivering an average surprise of 18.41%.
Immunocore (IMCR - Free Report) has an Earnings ESP of +30.39% and carries a Zacks Rank #3 at present.
The stock has increased by over 12% year to date. Immunocore beat on earnings in three of the trailing four quarters and missed in one, delivering an average surprise of 65.14%.